2 replies to this topic

[Phoenicis]

Is there any evidence to support the argument that Lisdexamfetamine dimesylatethis will contribute to aging in humans, when used in therapeutic doses daily?

Edited by Phoenicis, 28 July 2014 - 02:13 AM.

[Phoenicis]

That about 99% answers the question, but I need some references to help me with remaining 1%.

[gamesguru]

Not sure about the "over 9000". Compared to street users (200mg+ daily), therapeutic patients certainly put on less miles. I've just always avoided it, like I avoid alcohol.

If the medication is reducing ADHD-associated stress (getting frustrated at oneself for one's forgetfulness), it is probably doing more good than harm. Conversely, if you're feeling ramped-up, tense, and when it wears off, drained yet strangely unable to sleep well or long enough, that's probably your body saying "fuck adderall, it ain't right for me".

If you have a family history of Parkinson's, adderall is really contraindicated.

 

It is not known if there are similar alterations in the dopaminergic system of humans receiving long courses of prescription amphetamines ²³. However, in the most relevant animal model, 4 weeks of treatment with an amphetamine similar to the pharmaceutical Adderal produced plasma concentrations in adult baboons and squirrel monkeys that matched human ADHD patients after clinical treatment, and both species showed a 30−50% reduction in striatal dopamine, its major metabolite, its rate-limiting enzyme, its membrane transporter, and its vesicular transporter ⁵³. Although Parkinsonian symptoms generally require about twice as much dopamine reduction (80−90%), aging itself produces cumulative decrements in dopaminergic cells, dopamine metabolites and dopamine receptor binding ³⁸. These changes have been associated with modest cognitive and motor losses ¹⁷⁷, and age-linked reductions in frontal cortex metabolism ¹⁷⁸ similar to those characteristic of cocaine abusers ¹⁷⁹. Therefore, it would be of interest to explore whether there are any indications of delayed adverse motor or cognitive outcomes associated with very prolonged and high-dose stimulant exposure in older adults taking maintenance amphetamines, similar to what has been shown for aging boxers who accrued dopamine loss as a consequence of repeated closed head concussive trauma in their youth ¹⁸⁰.

 

Edited by dasheenster, 29 July 2014 - 09:02 PM.